Showing results (71-80 of 191) with videos related to

Sort By:
Pageof 20
Cancer Chemotherapy and Pharmacology|March 14, 2024
The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancersAllison Dunn, Naoko Takebe, Alice Chen, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 31, 2010
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerizationDana M Clausen, Jianxia Guo, Robert A Parise, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2024
Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in miceJoshua J Deppas, Brian F Kiesel, Jianxia Guo, et al.
Current Reviews in Clinical and Experimental Pharmacology|August 12, 2020
Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in MiceJan H Beumer, Jianxia Guo, Evan C Ray, et al.
Acta Biomaterialia|February 1, 2020
Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapyJingjing Sun, Zhuoya Wan, Yichao Chen, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 10, 2017
LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasmaBrian F Kiesel, Jonas Scemama, Robert A Parise, et al.
Cancer Chemotherapy and Pharmacology|December 12, 2018
A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancerLinda R Duska, Gina R Petroni, Heather Lothamer, et al.
Biomedical Chromatography : BMC|June 9, 2025
Quantitation of Tuvusertib (M1774) in Human Plasma by LC-MS/MSTien V Le, Robert A Parise, Julianne L Holleran, et al.
Pageof 20